Using image’s unique and patented adjuvant, delivery technology in combination with targeted MAGE-A derived peptides, imMAGE is developing a novel immunotherapeutic targeting triple negative breast cancer.
- Presenter: Mahesh Narayana CEO
- Commercial Catalyst: Jean Merrill and Caroline Hoedemaker
- Defined Milestone: Outline in detail steps required for next significant developmental breakthrough
- Targeted Completion: 1-3 months